This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Arden, N.K. Articles by Hughes, G.R.V. Search for Related Content PubMed PubMed Citation Articles by Arden, N.K. Articles by Hughes, G.R.V. Pubmed/NCBI databases Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Safety of Hormone Replacement Therapy (HRT) in Systemic Lupus Erythematosus (SLE)

Departments of Rheumatology and Lupus Arthritis Research Unit, St. Thomas' Hospital, London, UK

M.E. Lloyd

Departments of Rheumatology and Lupus Arthritis Research Unit, St. Thomas' Hospital, London, UK

T.D. Spector

Departments of Rheumatology and Lupus Arthritis Research Unit, St. Thomas' Hospital, London, UK

G.R.V. Hughes

Departments of Rheumatology and Lupus Arthritis Research Unit, St. Thomas' Hospital, London, UK

Despite its obvious benefits, many physicians are reluctant to prescribe HRT to patients with SLE. We have performed a retrospective study in 60 postmenopausal women with SLE including 30 HRT users and 30 never users. The patients were studied for 12 months after the initiation of HRT. The two groups were well matched for disease characteristics. The HRT users experienced significant improvements in general well being, libido and depression. There was no significant difference in any other parameter measured. There was no increase in the number of thrombo-embolic events in the user group despite 7 patients having a positive thrombophilia screen. In conclusion, in stable postmenopausal SLE HRT appears well tolerated and safe.

Key Words: Systemic lupus erythematosus • Hormone replacement therapy • Thromboembolic events

Lupus, Vol. 3, No. 1, 11-13 (1994)
DOI: 10.1177/096120339400300104


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Cohen-Solal, V Jeganathan, L Hill, D Kawabata, D Pinto-Rodriguez, C Grimaldi, and B Diamond Hormonal regulation of B-cell function and systemic lupus erythematosus Lupus, June 1, 2008; 17(6): 528 - 532. [Abstract] [PDF]

				J. P. Buyon, M. A. Petri, M. Y. Kim, K. C. Kalunian, J. Grossman, B. H. Hahn, J. T. Merrill, L. Sammaritano, M. Lockshin, G. S. Alarcon, et al. The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial Ann Intern Med, June 21, 2005; 142(12_Part_1): 953 - 962. [Abstract] [Full Text] [PDF]

				H. M. Perry III The Endocrinology of Aging Clin. Chem., August 1, 1999; 45(8): 1369 - 1376. [Abstract] [Full Text] [PDF]

				J. P. Buyon, H. M. Belmont, and K. C. Kalunian Postmenopausal Hormone Therapy and Systemic Lupus Erythematosus Ann Intern Med, December 15, 1995; 123(12): 961 - 961. [Full Text]